Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Top Cited Papers
- 25 May 2002
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (14), 2994-3008
- https://doi.org/10.1021/jm020057r
Abstract
F1000Prime Recommended Article: Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.Keywords
This publication has 31 references indexed in Scilit:
- Phenoxypyrimidine inhibitors of p38α kinaseBioorganic & Medicinal Chemistry Letters, 2001
- Protein kinase inhibitors: emerging pharmacophores 1997 - 2000Expert Opinion on Therapeutic Patents, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- p38 Mitogen-activated protein kinase as a target for drug discoveryDrugs of the Future, 1999
- 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase InhibitorJournal of Medicinal Chemistry, 1998
- Pyrroles and other heterocycles as inhibitors of P38 kinaseBioorganic & Medicinal Chemistry Letters, 1998
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- The syntheses of 5‐amino‐3‐t‐butylisothiazole and 3‐amino‐5‐t‐butylisothiazoleJournal of Heterocyclic Chemistry, 1989
- Stereoselective, Mild Reduction of Tosylhydrazones with Sodium Cyanoborohydride in Acidic MediaSynthesis, 1979
- Gauche effect. Stereochemical consequences of adjacent electron pairs and polar bondsAccounts of Chemical Research, 1972